NT PHARMA (01011) has announced the signing of a subscription agreement on February 9, 2026, with subscribers Hangzhou Jingwei Life Technology Co., Ltd. and Mr. Huang Jianshan. Under this agreement, the subscribers have conditionally agreed to subscribe, and the company has conditionally agreed to issue, unsecured two-year 5% interest-bearing convertible bonds due in 2028, with a total principal amount of HK$65 million. The gross proceeds and net proceeds from the bond issue are expected to be approximately HK$65 million and HK$64 million, respectively. The company intends to use the net proceeds for general working capital purposes and to repay borrowings. As of the date of this announcement, the total number of issued shares of the company is 674 million. Assuming (i) no other changes to the company's existing share capital; (ii) all conditions under the subscription agreement are met on or before the final deadline; and (iii) all conversion rights attached to the HK$65 million principal amount of bonds are fully exercised by the subscribers at a conversion price of HK$0.64 per share, the subscribers will hold an interest in 101.6 million shares. This represents approximately 15.06% of the company's issued share capital as of the announcement date, and approximately 13.09% of the company's issued share capital as enlarged by the allotment and issuance of conversion shares upon full exercise of the conversion rights under the bonds.